High-resolution HLA alleles and haplotypes in the United States population

Maiers, Martin; Gragert, Loren; Klitz, William

doi:10.1016/j.humimm.2007.04.005

Cited by 405 publications

(515 citation statements)

References 13 publications

Supporting

Mentioning

487

Contrasting

Unclassified

Order By: Relevance

“…An NMDP innovation called HapLogic SM predicts the likelihood of allele-level matching based on calculated HLA haplotype frequencies within major racial and ethnic populations. 9 Currently, HapLogic predicts high-resolution matching at HLA A, B and DRB1, but a future release in active development will also consider HLA C and DQ. TRANS Link allows the user to further customize the search results by prioritizing specific HLA loci or donor/UCB characteristics (age, sex, CMV status and so on).…”

Section: The Search Processmentioning

confidence: 99%

The US National Marrow Donor Program role in unrelated donor hematopoietic cell transplantation

Confer

Robinett

2008

Bone Marrow Transplant

View full text Add to dashboard Cite

The National Marrow Donor Program s (NMDP) is headquartered in Minneapolis, Minnesota, USA. Established in 1986, the NMDP currently operates the world's largest registry of unrelated adult donors and umbilical cord blood (UCB) units. Since its inception, the NMDP has benefited from continuous financial support provided by the US government through a series of contracts and grant awards. This funding has supported a large network of donor centers and the recruitment of millions of potential adult hematopoietic cell (HC) donors. More recently, the federal government has also supported a national registry for UCB units and expansion of the available UCB inventories. Today, the NMDP registry lists more than 6.7 million adult donors and 68 000 UCB units. Seventy-seven percent (5. NMDP history and statusThe National Marrow Donor Program s (NMDP) is headquartered in Minneapolis, Minnesota. It was established in 1986 through the combined efforts of families and physicians whose goal was a US national registry of adult, volunteer unrelated hematopoietic cell (HC) donors. Initial funding was provided through a grant to the American Red Cross. The history of NMDP's development has been recently reviewed. 1 Currently, the NMDP receives contracts from the US federal government to operate the CW Bill Young Cell Transplantation Program. This new program, named after Congressman Young who has been an ardent supporter of unrelated donor HCT and the NMDP, continues congressional support for a national BM donor registry and additionally calls for the development of enhanced capabilities to provide UCB units for transplantation. Funding provided under these contracts allows for the continued recruitment and support of adult donors as well as the collection, processing and storage of UCB units. The contracts further specify requirements for the identification and delivery of HC grafts, support of patients and the collection of comprehensive donor and recipient outcome data.In fulfillment of its mission and the government mandates, the NMDP functions as a network of participating organizations that perform the various functions involved in facilitating unrelated donor HC transplantation (HCT). The organizations include donor centers, which currently number 73 and are involved in the recruitment and subsequent management of adult volunteer donors. Donor centers are assisted in their recruitment efforts by 10 recruitment groups, which focus upon targeted recruitment within the US racial and ethnic minority populations. When an adult donor is matched with a recipient and a transplant occurs, the donor will donate either BM or PBSC, depending upon the wishes of the transplant physician. PBSC have been collected since 1999 and currently comprise nearly 70% of adult donor donations. BM collections occur at collection centers, which currently number 97, while PBSC collections occur at apheresis centers, which number 89. Twenty-four CB banks, which collect, store and manage UCB units, are currently participating with the NMDP. Transplant ce...

show abstract

Section: The Search Processmentioning

confidence: 99%

The US National Marrow Donor Program role in unrelated donor hematopoietic cell transplantation

Confer

Robinett

2008

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…2 The relative risk of developing BCR among HLA-A*29-positive individuals has been estimated to be 50-224. Although HLA-A*29 occurs commonly in all ethnic populations with a frequency of 4.5% in Caucasians, 3.5% in Africans and 1.7% in Asians, 3 BCR is almost exclusively found in Caucasians and is rare even in HLA-A*29-positive Caucasians, suggesting that host genetic factors besides HLA-A*29 play a role in BCR disease.…”

Section: Introductionmentioning

confidence: 99%

“…47 To examine whether KIR-HLA combinations confer risk for developing BCR, we typed KIR and HLA class I genes in patients and controls carrying HLA-A*29 as well as controls lacking HLA-A*29 from a French Caucasian population. This provides an appropriate system to assess the sole effect of KIR genes in conferring risk of BCR since the impact of HLA-A*29, the allele known to confer risk for disease, its linked HLA-B and HLA-C loci 3 and their force on coevolving KIR genes 48 are likely identical in patients and controls carrying HLA-A*29.…”

Section: Introductionmentioning

confidence: 99%

Combination of KIR and HLA gene variants augments the risk of developing birdshot chorioretinopathy in HLA-A*29-positive individuals

Levinson

Luo

et al. 2008

Genes Immun

View full text Add to dashboard Cite

“…Race frequencies are not utilized. Typings were verified against known haplotype associations 8, 9, 10, 11; however, no robust DPA and DPB haplotype associations are reported and typing at these loci was entered as provided by the source laboratory. The calculator further permits stratification of cPRA by ABO blood group and region within Canada (Figure S1), although these were not utilized in the present analysis.…”

Section: Methodsmentioning

confidence: 99%

cPRA Increases With DQA, DPA, and DPB Unacceptable Antigens in the Canadian cPRA Calculator

Tinckam

Liwski

Pochinco

et al. 2015

American Journal of Transplantation

View full text Add to dashboard Cite

A calculated panel reactive antibody (cPRA) estimates the percentage of donors with unacceptable antigens (UA) for a recipient. cPRA may be underestimated in transplant candidates with UA to DQA, DPA, and DPB if these are not included in the calculation program. To serve the National Canadian Transplant Programs, a cPRA calculator was developed with complete molecular typing for all donors at HLA‐A, B, C, DRB1, DRB3/4/5, DQA1, DQB1, DPA1, and DPB1, all resolved to serologic equivalents. The prevalence of UA at DQA, DPA and DPB was evaluated in a sensitized regional population. The impact of adding these additional UA to cPRA was calculated alone and in combination, and compared to the baseline cPRA for UA at A, B, C, DR, DR51/52/53, and DQ. Of 740 sensitized transplant candidates, 18% of total and 32% with cPRA≥95% had DQA UA. Twenty‐seven percent of total and 54% with cPRA≥95% had DPB UA. Of 280/740 subjects with these UA, 36/280 (13%) had cPRA increase of >20% when they were included, 7% increased cPRA to ≥80% and 6% to ≥95%. Inclusion of DQA, DPA, and DPB UA in Canadian cPRA calculations improves the accuracy of cPRA where these are relevant in allocation.

show abstract

High-resolution HLA alleles and haplotypes in the United States population

Cited by 405 publications

References 13 publications

The US National Marrow Donor Program role in unrelated donor hematopoietic cell transplantation

The US National Marrow Donor Program role in unrelated donor hematopoietic cell transplantation

Combination of KIR and HLA gene variants augments the risk of developing birdshot chorioretinopathy in HLA-A*29-positive individuals

cPRA Increases With DQA, DPA, and DPB Unacceptable Antigens in the Canadian cPRA Calculator

Contact Info

Product

Resources

About